For decades, the medical answer to a worn-out knee joint has been the same: manage pain with anti-inflammatory drugs and physical therapy until the cartilage is gone, then replace the joint with titanium and plastic. That answer — joint replacement surgery, performed more than 700,000 times a year in the United States alone — may be approaching obsolescence. A landmark study published June 12, 2026 in the journal Science by researchers at Stanford Medicine demonstrates that a single injection blocking a protein linked to aging can not only stop the progression of arthritis but actively reverse cartilage loss that had already occurred — and that human cartilage tissue responds to the same treatment.
The findings, led by Dr. Helen Blau, director of the Baxter Laboratory for Stem Cell Biology at Stanford University School of Medicine, and Dr. Nidhi Bhutani, professor of orthopedic surgery, center on a single enzyme: 15-hydroxy prostaglandin dehydrogenase, known as 15-PGDH. This enzyme — which increases with age in multiple tissues and which the research team previously identified as a key driver of tissue decline in older organisms — acts as a biological brake on the body's ability to regenerate cartilage. As 15-PGDH accumulates in aging cartilage tissue, it progressively disables the chondrocytes (cartilage-producing cells) that would normally maintain and repair the joint surface.
When the team injected a 15-PGDH inhibitor directly into the knee joints of old mice with age-related cartilage loss, the results were, by their own description, astonishing. "We were surprised," Dr. Blau told KTVU FOX 2. "We were amazed to see that extent of regeneration of the cartilage." The treatment restored healthy, shock-absorbing cartilage in joints that had been progressively losing it through normal aging — cartilage that looked functionally and histologically similar to young cartilage. In a separate set of experiments, the treatment was administered to mice after ACL-like knee injuries — the most common injury mechanism for human osteoarthritis development — and it prevented arthritis from forming in approximately 50 percent of treated animals.
The Human Tissue Breakthrough
What converts this from a promising mouse study into a genuine translational breakthrough is the human tissue data. The Stanford team obtained cartilage samples from human patients undergoing knee replacement surgeries — tissue that is so degenerated that it has been surgically removed because no medical treatment could restore it. They applied the 15-PGDH inhibitor to these human cartilage samples in the laboratory and observed the same regenerative response: chondrocytes in the human tissue began forming new, functional cartilage.
The mechanism by which this occurs is also newly documented and conceptually significant. Unlike most tissue repair in the body, which relies on stem cells differentiating into specialized repair cells, cartilage appears to regenerate through a different pathway. Existing chondrocytes — the cells already present in cartilage — shift their gene expression patterns to behave more like younger cells, effectively resetting their biological clock without requiring an external cell source. This discovery represents what the researchers call "a new way of regenerating adult tissue" — one that bypasses the supply limitations of stem cell therapy.
"Until now, there has been no drug that directly treats the cause of cartilage loss. But this gerozyme inhibitor causes a dramatic regeneration of cartilage beyond that reported in response to any other drug or intervention," said Professor Blau. The 15-PGDH inhibitor is already in Phase 1 clinical trials through Epirium Bio for a different indication — age-related muscle weakness — and the Phase 1 data confirm the drug is safe and pharmacologically active in healthy human volunteers. "Our hope is that a similar trial will be launched soon to test its effect in cartilage regeneration. We are very excited about this potential breakthrough. Imagine regrowing existing cartilage and avoiding joint replacement," Dr. Blau said.
What This Means for the 60 Million Americans With Osteoarthritis
Osteoarthritis is a degenerative joint disease affecting approximately one in five American adults — roughly 60 million people — and generates an estimated $65 billion each year in direct health care costs. It is the leading cause of disability among adults over 45, driving decisions that limit mobility, independence, and quality of life. Current treatments range from over-the-counter anti-inflammatory medications to corticosteroid injections to joint replacement surgery — none of which restore cartilage or address the underlying biology of joint degeneration.
No drug has ever been approved by the FDA to slow, stop, or reverse cartilage loss in osteoarthritis. If the 15-PGDH inhibitor advances through human clinical trials successfully, it would represent not just a new drug but an entirely new treatment paradigm — one in which osteoarthritis is treated biologically rather than managed mechanically.
Frequently Asked Questions
Q: What did Stanford scientists discover about cartilage and arthritis?
A: They found that blocking an aging-related enzyme called 15-PGDH with a single injection can fully reverse age-related cartilage loss in old mice, prevent post-injury arthritis in 50% of cases, and trigger cartilage regeneration in human knee tissue samples. The study was published in Science on June 12, 2026.
Q: Does this treatment work in human tissue?
A: Yes. Human cartilage samples from knee replacement surgeries — already so degenerated that surgical removal was necessary — began forming new cartilage when exposed to the 15-PGDH inhibitor in laboratory experiments.
Q: How does this compare to existing arthritis treatments?
A: No existing FDA-approved drug can slow or reverse cartilage loss. All current treatments manage symptoms or replace damaged joints. The 15-PGDH inhibitor would be the first treatment to restore cartilage biologically.
Q: Is this available for patients now?
A: No. The 15-PGDH inhibitor (licensed to Epirium Bio) is in Phase 1 clinical trials for muscle weakness, where it has shown safety in healthy volunteers. A separate clinical trial for cartilage regeneration is being planned.
Q: When might a cartilage regeneration drug become available?
A: Clinical trials specifically for cartilage regeneration have not yet begun. If trials proceed rapidly and successfully, treatments could potentially reach patients in 5 to 10 years, though timelines are inherently uncertain.
